Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03551249 |
Recruitment Status :
Completed
First Posted : June 11, 2018
Last Update Posted : March 5, 2024
|
Sponsor:
InSightec
Information provided by (Responsible Party):
InSightec
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | April 17, 2018 | ||||||
First Posted Date ICMJE | June 11, 2018 | ||||||
Last Update Posted Date | March 5, 2024 | ||||||
Actual Study Start Date ICMJE | March 26, 2019 | ||||||
Actual Primary Completion Date | December 31, 2023 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Device and procedure related adverse events [ Time Frame: Throughout the study, approximately 12 months. ] The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE
|
||||||
Original Primary Outcome Measures ICMJE |
Device and procedure related adverse events [ Time Frame: Throughout the study, approximately 12 months. ] The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE v4.0
|
||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging [ Time Frame: At the time of each ExAblate MRgFUS procedure ] The repeatability of BBB disruption will be evaluated at each of the 6 procedures and will be evaluated through assessment of post-procedure contrast-enhanced MR imaging.
|
||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption | ||||||
Official Title ICMJE | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy | ||||||
Brief Summary | The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy. | ||||||
Detailed Description | This is a prospective, multi-center, single-arm study to establish the safety and feasibility of BBB (blood brain barrier) disruption along the periphery of tumor resection cavity using the ExAblate Neuro Model 4000 Type 2 (220 kHz) system. For this study, patients will be eligible to enroll in the study prior to beginning the planned adjuvant TMZ chemotherapy phase of treatment. Of note, only patients who are deemed eligible for adjuvant TMZ will be eligible for enrollment. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Not Applicable | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE | Device: Focused ultrasound (FUS)
FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
Other Name: ExAblate, Type 2
|
||||||
Study Arms ICMJE | Experimental: Focused Ultrasound (FUS)
The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
Intervention: Device: Focused ultrasound (FUS)
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE |
20 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Actual Study Completion Date ICMJE | December 31, 2023 | ||||||
Actual Primary Completion Date | December 31, 2023 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years to 80 Years (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03551249 | ||||||
Other Study ID Numbers ICMJE | BT008 | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Current Responsible Party | InSightec | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor ICMJE | InSightec | ||||||
Original Study Sponsor ICMJE | Same as current | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
|
||||||
PRS Account | InSightec | ||||||
Verification Date | March 2024 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |